Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance (original) (raw)
REFERENCES
J. L. Kelsey and G. S. Berkowitz (1988). Breast cancer epidemiology. Cancer Res.48:5615–5623. Google Scholar
I. H. Russo and J. Russo (1998). Role of hormones in mammary cancer initiation and progression. J. Mam. Gland Biol. Neoplasia3(1):49–61. Google Scholar
K. R. Yamamoto (1985). Steroid receptor regulated transcription of specific genes and gene networks. Ann. Rev. Genet.19:209–252. Google Scholar
D. J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R. M. Evans (1995). The nuclear receptor superfamily: The second decade. Cell83:835–839. Google Scholar
B. Blumberg and R. M. Evans (1998). Orphan nuclear receptors: New ligands and new possibilities. Genes Dev.12:3149–3155. Google Scholar
J. W. R. Schwabe, L. Chapman, J. T. Finch, and D. Rhodes (1993). The crystal structure of the estrogen receptor DNAbinding domain bound to DNA: How receptors discriminate between their response elements. Cell70:567–578. Google Scholar
A. M. Brzozowski, A. C. W. Pike, Z. Dauter, R. E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. L. Green, J.-A. Gustafsson, and M. Carlquist (1997). Molecular basis of agonism and antagonism of the oestrogen receptor. Nature389: 753–758. Google Scholar
A. K. Shiau, D. Barstad, P. M. Loria, L. Cheng, P. J. Kushner, D. A. Agard, and G. L. Greene (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell95:927–937. Google Scholar
D. M. Tanenbaum, Y. Wang, S. P. Williams, and P. B. Sigler (1998). Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. U.S.A.95:5998–6003. Google Scholar
H. Gronemeyer (1991). Transcription activation by estrogen and progesterone receptors. Ann. Rev. Biochem.25:89–123. Google Scholar
M. J. Tsai and B. W. O'Malley (1994). Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Ann. Rev. Biochem.63:451–486. Google Scholar
M. Beato, P. Herlich, and G. Schutz (1995). Steroid hormone receptors: Many actors in search of a plot. Cell83:851–857. Google Scholar
S. Dauvois, P. S. Danielian, R. White, and M. G. Parker (1992). Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A.89:4037–4041. Google Scholar
S. Dauvois, R. White, and M. G. Parker (1993). The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci.106:1377–1388. Google Scholar
Y. Sadovsky, P. Webb, G. Lopez, J. D. Baxter, P. M. Fitzpatrick, E. Gizang-Ginsberg, V. Cavailles, M. G. Parker, and P. J. Kushner (1995). Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein. Mol. Cell Biol.15:1554–1563. Google Scholar
N. H. Ing, J. M. Beekman, S. Y. Tsai, M J. Tsai, and B. W. O'Malley (1992). Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J. Biol. Chem.267:17617–17623. Google Scholar
X. Jacq, C. Brou, Y. Lutz, I. Davidson, P. Chambon, and L. Tora (1994). Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell79:107–117. Google Scholar
B. Hanstein, R. Eckner, J. DiRenzo, S. Halachmi, H. Liu, B. Searcy, R. Kurokawa, and M. Brown (1996). p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. U.S.A.93:11540–11545. Google Scholar
L. P. Freedman (1999). Increasing the complexity of coactivation in nuclear receptor signaling. Cell97:5–8. Google Scholar
C. K. Glass and M. G. Rosenfeld (2000). The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev.14:121–141. Google Scholar
T. Perlmann and R. M. Evans (1988). Nuclear receptors in Sicily: All in the famiglia. Cell90:391–397. Google Scholar
D. P. Edwards (2000). The role of coactivators and corepressors in biology and mechanism of action of steroid hormone receptors. J. Mam. Gland Biol. Neoplasia5(3)(1)xx–xx. Google Scholar
A. M. Brzozowski, A. C. W. Pike, Z. Dauter, R. E. Hubbard, T. Bonn, O. Engstrom, L. Ohman, G. L. Green, J.-A. Gustafsson, and M. Carlquist (1997). Molecular basis of agonism and antagonism of the oestrogen receptor. Nature389:753–758. Google Scholar
D. Moras and H. Gronemeyer (1998). The nuclear receptor ligand-binding domain: Structure and function. Curr. Opin. Cell Biol.10:384–391. Google Scholar
D. Ricketts, L. Turnbull, G. Ryall, R. Bakhshi, N. S. B. Rawson, J.-C. Gazet, C. Nolan, and R. CCoombes (1991). Estrogen and progesterone receptors in the normal female breast. Cancer Res.51:1817–1822. Google Scholar
A. S. Khan, M. A. M. Rogers, K. K. Khurana, M. M. Meguid, and P. J. Numann (1998). Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst.90:37–42. Google Scholar
I. F. O'Connor, M. V. Shembekar, and S. Shousha (1998). Breast carcinoma developing in patients on hormone replacement therapy: A histological and immunohistological study. J. Clin. Pathol.51(12):935–938. Google Scholar
C. Markopoulos, U. Berger, P. Wilson, J.-C. Gazet, and R. C. Coombes (1988). Estrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Brit. Med. J.296:1349–1351. Google Scholar
H. Kirkman (1959). Induction of renal tumors by estrogens. Natl. Cancer Inst. Monogr.1:1–59. Google Scholar
E. L. Cavalieri, D. E. Stack, P. D. Devanesan, R. Todorovic, I. Dwivedy, S. Higginbothan, S. L. Johansson, K. D. Patil, M. L. Gross, J. K. Gooden, R. Ramanathan, R. L. Cerny, and E. G. Rogan (1997). Molecular origin of cancer: Catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. U.S.A.94:10937–10942. Google Scholar
I. Dwivedy, P. Devanesan, P. Cremonesi, E. Rogan, and E. Cavalieri (1992). Synthesis and characterization of estrogen 2, 3-and 3, 4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem. Res. Toxicol.5(6):828–833. Google Scholar
C. L. Hayes, D. C. Spink, B. C. Spink, J. Q. Cao, N. J. Walker, and T. R. Sutter (1996). 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. U.S.A.93(18):9776–9781. Google Scholar
C. S. Huang, H. D. Chern, K. J. Chang, C. W. Cheng, S. M. Hsu, and C. Y. Shen (1999). Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility. Cancer Res.59(19):4870–4875. Google Scholar
J. L. Stanford, M. Szklo, and L. A. Brinton (1986). Estrogen receptors and breast cancer. Epidemiol Rev.8:42–59. Google Scholar
L. A. Habel and J. L. Stanford (1993). Hormone receptors and breast cancer. Epidemiol Rev.15:209–219. Google Scholar
A. Zeleniuch-Jacquotte, P. Toniolo, M. Levitz, R. E. Shore, K. L. Koenig, and S. Banarjee et al. (1995). Endogenous estrogens and risk of breast cancer by estrogen receptor status: A prospective study in postmenopausal women. Cancer Epidemiol. Biomarkers Prev.4:857–860. Google Scholar
J. F. R. Robertson (1996). Estrogen receptor: a stable phenotype in breast cancer. Brit. J. Cancer73:5–12. Google Scholar
T. J. Powles, C. Gordon, and R. C. Coombes (1982). Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimidedanazol compared to tamoxifen used alone. Cancer Res.42(Suppl):34158–34195. Google Scholar
R. C. Coombes, S. W. M. Hughes, and M. Dowsett (1992). 4-hydroxy-androstenedione: A new treatment for Postmenopausal patients with breast cancer. Eur. J. Cancer28A: 1963–1965. Google Scholar
R. E. Taylor, T. J. Powles, J. Humphreys, R. Bettelheim, M. Dowsett, A. J. Casey, A. M. Neville, and R. C. Coombes (1982). Effects of endocrine therapy on steriod-receptor content of breast cancer. Brit. J. Cancer45:80–85. Google Scholar
R. B. Clarke, I. J. Laidlaw, L. J. Jones, A. Howell, and E. Anderson (1993). Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Brit. J. Cancer67:606–611. Google Scholar
P. A. Murray, K. Gomm, D. Ricketts, T. Powles, and R. C. C. Coombes (1994). The effect of endocrine therapy on the levels of estrogen and progesterone receptor and transforming growth factor-β1 inmetastatic human breast cancer: An immunocytochemical study. Eur. J. Cancer30:1218–1222. Google Scholar
Early Breast Cancer Trialists' Collaborative Group (1998). Polychemo-therapy for early breast cancer: An overview of the randomised trials. Lancet352:930–942. Google Scholar
R. C. Coombes, T. J Powles, U. Berger, P. Wilson, R. A. McClelland, J.-C. Gazet, P. A. Trott, and H. T. Ford (1987). Prediction of endocrine response in breast cancer by immunocytochemical detection of estrogen receptor in fine needle aspirates. Lancet2:701–703. Google Scholar
T. A. Hopp and S. A. W. Fuqua (1998). Estrogen receptor variants. J. Mam. Gland Biol. Neoplasia3(1):73–83. Google Scholar
C. K. Watts, M. L. Handel, R. J. King, and R. L. Sutherland (1992). Estrogen receptor gene structure and function in breast cancer. J. Steroid Biochem. Mol. Biol.41(38):529–536. Google Scholar
S. Saji, E. V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J.-A. Gustafsson (2000). Estrogen receptors α and β in the rodent mammary gland. Med. Sci.97:337–342. Google Scholar
P. Pace, J. Taylor, S. Suntharalingam, R. C. Coombes, and S. Ali (1997). Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor α. J. Biol. Chem.272:25832–25838. Google Scholar
S. M. Cowley, S. Hoare, S. Mosselman, and M. G. Parker (1997). Estrogen receptor α and β form heterodimers on DNA. J. Biol. Chem.272:19858–19862. Google Scholar
S. Ogawa, S. Inoue, T. Watanabe, H. Hiroi, A. Orimo, T. Hosoi, Y. Ouchi, and M. Muramatsu (1998). The complete primary structure of human estrogen receptor β (hERBβ) and its heterodimerization with ERα in vivo and in vitro. Biochem. Biophys. Res. Commun.243:122–126. Google Scholar
K. Pettersson, K. Grandien, G. G. Kuiper, and J. A. Gustafsson (1997). Mouse estrogen receptor β forms estrogen response element-binding heterodimers with estrogen receptor β. Mol. Endocrinol.10:499–507. Google Scholar
A. J. Desai, Y. A. Luqmani, J. E. Walters, R. C. Coope, B. Dagg, J. J. Gomm, P. E. Pace, C. N. Rees, S. Shousha, N. P. Groome, R. C. Coombes, and S. Ali (1997). Presence of exon 5-deleted oestrogen receptor in human breast cancer: Functional analysis and clinical significance. Brit. J. Cancer75:1173–1184. Google Scholar
H. Ohlsson, A. E. Lykkesfeldt, M. W. Madsen, and P. Briand (1998). The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1. Cancer Res.58(19):4264–4268. Google Scholar
T. Hunter and M. Karin (1992). The regulation of transcription by phosphorylation. Cell70:375–387. Google Scholar
S. P. Jackson (1992). Regulating transcription factor activity by phosphorylation. Trends Cell Biol.2:104–108. Google Scholar
M. Karin (1994). Signal transduction from the cell surface to the nucleus through phosphorylation of transcription factors. Curr. Opin. Cell Biol.6:415–424. Google Scholar
C. L. Smith (1998). Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod.58:627–632. Google Scholar
D. Shao and M. A. Lazar (1999). Modulating nuclear receptor function: May the phos be with you. J. Clin. Invest.103:1617–1618. Google Scholar
K. E. Weis, K. Ekena, J. A. Thomas, G. Lazennec, and B. S. Katzenellenbogen (1996). Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol. Endocrinol.10: 1388–1398. Google Scholar
R. White, M. Sjoberg, E, Kalkhoven, and M. G. Parker (1997). Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine. EMBO J.16:1427–1435. Google Scholar
Q. X. Zhang, A. Borg, D. M. Wolf, S. Oesterreich, and S. A. Fuqua (1997). An estrogen receptor mutant with strong hormone-independent activity from ametastatic breast cancer. Cancer Res.57(7):1244–1249. Google Scholar
S. F. Arnold, M. Melamed, D. P. Vorojeikina, A. C. Notides, and S. Sasson (1997). Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation. Mol. Encocrinol.11(1):48–53. Google Scholar
D. Chen, P. E. Pace, R. C. Coombes, and S. Ali (1999). Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol. Cell. Biol.19:1002–1015. Google Scholar
S. Ali, D. Metzger, J.-M Bornert, and P. Chambon (1993). Phosphorylation of the human oestrogen receptor. Identification of a phosphorylation site required for transactivation. EMBO J.12:1153–1160. Google Scholar
P. Le Goff, M. M. Montano, D. J. Schodin, and B. S. Katzenellenbogen (1994). Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J. Biol. Chem.269:4458–4466. Google Scholar
P. B. Joel, J. Smith, T. W. Sturgill, T. L. Fisher, J. Blenis, and D. A. Lannigan (1998). pp90rsk1 regulates estrogen receptormediated transcription through phosphorylation of Ser-167. Mol. Cell Biol.18:1978–1984. Google Scholar
I. Rogatsky, J. M. Trowbridge, and M. J. Garabedian (1999). Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J. Biol. Chem.274:22296–222302. Google Scholar
S. Kato, H. Endoh, Y. Masuhiro, T. Kitamoto, S. Uchiyama, H. Sasaki, S. Masushige, Y. Gotoh, E. Nishida, H. Kawashima, D. Metzger, and P. Chambon (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science1995:1491–1494. Google Scholar
G. Bunone, P.-E. Briand, R. J. Miksicek, and D. Picard (1996). Activation of the unliganded estrogen receptor by EFG involves the MAP kinase pathway and direct phosphorylation. EMBO J.15(9):2174–2183. Google Scholar
P. B. Joel, A. M. Traish, and D. A. Lannigan (1998). Estradiolinduced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J. Biol. Chem.273:13317–13323. Google Scholar
D. Chen, T. Riedl, E. Washbrook, P. E. Pace, R. C. Coombes, J. M. Egly, and S. Ali (2000). Activation of Estrogen Receptor a by S118 Phosphorylation Involves a Ligand-Dependent Interaction with TFIIH and Participation of CDK7. Mol. Cell6:127–137. Google Scholar
P. C. Gordge, M. J. Hulme, R. A. Clegg, and W. R. Miller (1996). Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur. J. Cancer32A(12):2120–2126. Google Scholar
W. R. Miller, R. A. Elton, J. M. Dixon, U. Chetty, and D. M. Watson (1990). Cyclic AMP binding proteins and prognosis in breast cancer. Brit. J. Cancer61:263–266. Google Scholar
V. S. Sivaraman, H.-Y. Wang, G. J. Nuovo, and C. C. Malbon (1997). Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest.99:1478–1483. Google Scholar
A. S. Coutts and L. C. Murphy (1998). Elevated mitogenactivated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res.58:4071–4074. Google Scholar
O. M. Sobulo, J. Borrow, R. Tomek, S. Reshmi, A. Harden, B. Schlegelberger, D. Housman, N. A. Doggett, J. D. Rowley, and N. J. Zeleznik-Le (1997). MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc. Natl. Acad. Sci. U.S.A.94:8732–8737. Google Scholar
S. L. Anzick, J. Kononen, R. L. Walker, D. O. Azorsa, M. M. Tanner, X. Y. Guan, G. Sauter, O. P. Kallioniemi, J. M. Trent, and P. S. Meltzer (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science277:965–968. Google Scholar
J. Xu, Y. Qiu, F. J. DeMayo, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley (1998). Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science279:1922–1925. Google Scholar
J. Xu et al. (2000). The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl. Acad. Sci. U.S.A.97(12):6379–6384. Google Scholar
R. M. Lavinsky, K. Jepsen, T. Heinzel, J. Torchia, T. M. Mullen, R. Schiff, A. L. DelRio, M. Ricote, S. Ngo, J. Gemsch, S. G. Hilsenbeck, C. K. Osborne, C. K. Glass, M. G. Rosenfeld, and D. W. Rose (1998). Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. U.S.A.95:2920–2925. Google Scholar
R. C. Stein, M. Dowsett, A. Hedley, J.-C. Gazet, H. T. Ford, and R. C. Coombes (1990). The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Brit. J. Cancer62:679–683. Google Scholar
P. E. Lonning, S. Jacobs, A. Jones et al. (1991). The influence of CGS 16949A on peripheral aromatization in breast cancer patients. Brit. J. Cancer63:789–793. Google Scholar
M. Dowsett, D. Doody, S. Miall, A. Howes, J. English, and R. C. Coombes (1999). Vorozole results in greater estrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res. Treat.56:25–34. Google Scholar
C. Harper-Wynne and R. C. Coombes (1999). Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilized on formestane therapy. Eur. J. Cancer35:744–746. Google Scholar
R. Murray and P. Pitt (1995). Aromatase inhibition with 4-OH Androstendione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res. Treat.35:249–253. Google Scholar
B. Thurlimann, R. Paridaens, and D. Serin et al. (1997). Thirdline hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multi center multinational study. Eur. J. Cancer33:1767–1773. Google Scholar
M.-H. Jeng, M. A. Shupnik, T. P. Bender, E. H. Westin, D. Bandyopadhyay, R. Kumar, S. Masamura, and R. J. Santen (1998). Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology139(10):4164–4174. Google Scholar